Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junichi Shindoh

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 23, 2025
Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational StudyTakamichi Ishii, Junichi Shindoh, Ikuo Nakamura, et al.
Liver Cancer|July 11, 2020
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall PrognosisYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Liver Cancer|June 19, 2024
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)Akihiko Ichida, Junichi Arita, Etsuro Hatano, et al.
Cancer|July 4, 2013
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinomaAhmed O Kaseb, Junichi Shindoh, Yehuda Z Patt, et al.
Oncology|September 14, 2022
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based AnalysisNozomu Muraishi, Yusuke Kawamura, Norio Akuta, et al.
Cancers|August 12, 2023
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular CarcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|March 1, 2022
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Annals of Surgery|May 24, 2014
Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter studyJunichi Shindoh, Xabier de Aretxabala, Thomas A Aloia, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 30, 2018
Conceptual framework of middle hepatic vein anatomy as a roadmap for safe right hepatectomySatoshi Ogiso, Masayuki Okuno, Junichi Shindoh, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 23, 2025
Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational StudyTakamichi Ishii, Junichi Shindoh, Ikuo Nakamura, et al.
Liver Cancer|July 11, 2020
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall PrognosisYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Liver Cancer|June 19, 2024
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)Akihiko Ichida, Junichi Arita, Etsuro Hatano, et al.
Cancer|July 4, 2013
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinomaAhmed O Kaseb, Junichi Shindoh, Yehuda Z Patt, et al.
Oncology|September 14, 2022
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based AnalysisNozomu Muraishi, Yusuke Kawamura, Norio Akuta, et al.
Cancers|August 12, 2023
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular CarcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|March 1, 2022
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Annals of Surgery|May 24, 2014
Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter studyJunichi Shindoh, Xabier de Aretxabala, Thomas A Aloia, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 30, 2018
Conceptual framework of middle hepatic vein anatomy as a roadmap for safe right hepatectomySatoshi Ogiso, Masayuki Okuno, Junichi Shindoh, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Pageof 18